Why Shares in AbbVie Soared 18% in September
A patent victory and pipeline advances that could lead to billions in additional sales helped catapult AbbVie Inc. (NYSE: ABBV) shares 18% higher in September, according to S&P Global Market Intelligence.
On September 7, the U.S. Patent Office refused competitor Coherus's request for an inter partes review of AbbVie's U.S. Patent 9,085,619. The decision added strength to claims by AbbVie's management that it can keep Humira copy-cats out of the market in the U.S. until the end of 2022.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Amgen Inc. Stock
€308.45
0.230%
The stock is an absolute favorite of our community with 25 Buy predictions and no Sell predictions.
On the other hand, the target price of 304 € is below the current price of 308.45 € for Amgen Inc., so the potential is actually -1.44%.
